US5456663A
(en)
*
|
1984-05-25 |
1995-10-10 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
US5882330A
(en)
*
|
1984-05-25 |
1999-03-16 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
US6448392B1
(en)
*
|
1985-03-06 |
2002-09-10 |
Chimerix, Inc. |
Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
|
DE68927479T2
(de)
*
|
1988-05-02 |
1997-04-03 |
Phanos Tech Inc |
Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
|
US5817638A
(en)
*
|
1988-07-07 |
1998-10-06 |
Nexstar Pharmaceuticals, Inc. |
Antiviral liponucleosides: treatment of hepatitis B
|
US6252060B1
(en)
|
1988-07-07 |
2001-06-26 |
Nexstar Pharmaceuticals, Inc. |
Antiviral liponucleosides: treatment of hepatitis B
|
US6599887B2
(en)
|
1988-07-07 |
2003-07-29 |
Chimerix, Inc. |
Methods of treating viral infections using antiviral liponucleotides
|
US5216142A
(en)
*
|
1989-04-17 |
1993-06-01 |
Efamol Holdings Plc |
Anti-virals
|
ZA902710B
(en)
*
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
US5411947A
(en)
*
|
1989-06-28 |
1995-05-02 |
Vestar, Inc. |
Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
|
US5194654A
(en)
*
|
1989-11-22 |
1993-03-16 |
Vical, Inc. |
Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
|
US5463092A
(en)
*
|
1989-11-22 |
1995-10-31 |
Vestar, Inc. |
Lipid derivatives of phosphonacids for liposomal incorporation and method of use
|
CA2079109A1
(en)
*
|
1990-03-29 |
1991-09-30 |
John A. Latham |
Oligonucleotide-transport agent disulfide conjugates
|
DE4013632A1
(de)
*
|
1990-04-27 |
1991-10-31 |
Max Planck Gesellschaft |
Liposomen mit positiver ueberschussladung
|
CA2042093C
(en)
*
|
1990-05-09 |
2002-12-24 |
Gyula Hadlaczky |
Cell line carrying an excess of mammalian centromeres
|
JPH0421694A
(ja)
*
|
1990-05-16 |
1992-01-24 |
Asahi Chem Ind Co Ltd |
新規なヌクレオシド―リン脂質複合体
|
EP0533825B1
(de)
*
|
1990-06-15 |
1996-04-24 |
Wake Forest University |
Kovalente-ther lipidnukleosid-konjugate
|
US5563257A
(en)
*
|
1990-08-20 |
1996-10-08 |
Boehringer Mannheim Gmbh |
Phospholipid derivatives of nucleosides
|
DE4026265A1
(de)
*
|
1990-08-20 |
1992-02-27 |
Boehringer Mannheim Gmbh |
Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
|
US5543389A
(en)
*
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization |
Covalent polar lipid-peptide conjugates for use in salves
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5827819A
(en)
*
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
US5256641A
(en)
*
|
1990-11-01 |
1993-10-26 |
State Of Oregon |
Covalent polar lipid-peptide conjugates for immunological targeting
|
GB9111967D0
(en)
*
|
1991-06-04 |
1991-07-24 |
Erba Carlo Spa |
2,5'-nucleotide analogs as antiviral agents
|
AU668873B2
(en)
*
|
1991-07-12 |
1996-05-23 |
Chimerix, Inc. |
Antiviral liponucleosides: treatment of hepatitis B
|
US5554728A
(en)
*
|
1991-07-23 |
1996-09-10 |
Nexstar Pharmaceuticals, Inc. |
Lipid conjugates of therapeutic peptides and protease inhibitors
|
GB2260319B
(en)
*
|
1991-10-07 |
1995-12-06 |
Norsk Hydro As |
Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
|
US5879700A
(en)
*
|
1991-10-15 |
1999-03-09 |
Hostetler; Karl Y. |
Nucleoside analogue phosphates for topical use
|
US5580571A
(en)
*
|
1991-10-15 |
1996-12-03 |
Hostetler; Karl Y. |
Nucleoside analogues
|
DE4204031A1
(de)
*
|
1992-02-12 |
1993-08-19 |
Boehringer Mannheim Gmbh |
Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
|
DE4204032A1
(de)
*
|
1992-02-12 |
1993-08-19 |
Boehringer Mannheim Gmbh |
Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
|
US6733776B1
(en)
|
1992-04-02 |
2004-05-11 |
Anticancer, Inc. |
Method for promoting hair growth
|
US5792751A
(en)
*
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
US6080734A
(en)
*
|
1992-08-08 |
2000-06-27 |
Roche Diagnostic Gmbh |
Liponucleotides of seco-nucleosides, their production as well as their use as antiviral pharmaceutical agents
|
DE4226279A1
(de)
*
|
1992-08-08 |
1994-02-10 |
Boehringer Mannheim Gmbh |
Liponucleotide von Seco-Nucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
|
US5512671A
(en)
*
|
1993-02-16 |
1996-04-30 |
Wake Forest University |
Ether lipid-nucleoside covalent conjugates
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
CA2157793C
(en)
*
|
1993-03-09 |
1999-07-13 |
James E. Woiszwillo |
Macromolecular microparticles and methods of production
|
ES2067395B1
(es)
*
|
1993-03-10 |
1996-01-01 |
Norsk Hydro As |
Derivados de nucleosidos o analogos a nucleosidos.
|
IL105244A
(en)
*
|
1993-03-31 |
2003-07-31 |
Dpharm Ltd |
Prodrugs with enhanced penetration into cells
|
EP0690068A4
(de)
*
|
1993-03-18 |
1996-07-31 |
Akira Matsuda |
2'-methyliden nukleotid-verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
|
US6413949B1
(en)
|
1995-06-07 |
2002-07-02 |
D-Pharm, Ltd. |
Prodrugs with enhanced penetration into cells
|
US5484911A
(en)
*
|
1993-04-01 |
1996-01-16 |
Health Research, Inc. |
Nucleoside 5'-diphosphate conjugates of ether lipids
|
US7556825B2
(en)
*
|
1993-04-02 |
2009-07-07 |
Anticancer, Inc. |
Method for promoting hair growth
|
CA2159626C
(en)
*
|
1993-04-02 |
2001-10-02 |
Lingna Li |
Method for delivering beneficial compositions to hair follicles
|
GB9307043D0
(en)
*
|
1993-04-05 |
1993-05-26 |
Norsk Hydro As |
Chemical compounds
|
GB9309787D0
(en)
*
|
1993-05-12 |
1993-06-23 |
Rhone Poulenc Chemicals |
Purification of fluoronucleosides
|
US6015573A
(en)
*
|
1993-05-12 |
2000-01-18 |
Hostetler; Karl Y. |
Nucleoside phosphate therapy for viral infection
|
US5717086A
(en)
*
|
1993-05-12 |
1998-02-10 |
Rhone-Poulenc Chemicals Limited |
Preparation of fluoro-nucleosides and intermediates for use therein
|
US5654286A
(en)
*
|
1993-05-12 |
1997-08-05 |
Hostetler; Karl Y. |
Nucleotides for topical treatment of psoriasis, and methods for using same
|
WO1994026273A1
(en)
*
|
1993-05-12 |
1994-11-24 |
Hostetler Karl Y |
Acyclovir derivatives for topical use
|
DE4321978A1
(de)
*
|
1993-07-01 |
1995-01-12 |
Boehringer Mannheim Gmbh |
Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
|
US20020120130A1
(en)
*
|
1993-09-10 |
2002-08-29 |
Gilles Gosselin |
2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
|
US5962427A
(en)
|
1994-02-18 |
1999-10-05 |
The Regent Of The University Of Michigan |
In vivo gene transfer methods for wound healing
|
US5763416A
(en)
|
1994-02-18 |
1998-06-09 |
The Regent Of The University Of Michigan |
Gene transfer into bone cells and tissues
|
US20020193338A1
(en)
*
|
1994-02-18 |
2002-12-19 |
Goldstein Steven A. |
In vivo gene transfer methods for wound healing
|
US6074840A
(en)
|
1994-02-18 |
2000-06-13 |
The Regents Of The University Of Michigan |
Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
|
US5942496A
(en)
|
1994-02-18 |
1999-08-24 |
The Regent Of The University Of Michigan |
Methods and compositions for multiple gene transfer into bone cells
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US7135584B2
(en)
|
1995-08-07 |
2006-11-14 |
Wake Forest University |
Lipid analogs for treating viral infections
|
EP1852121A3
(de)
|
1994-08-29 |
2007-11-21 |
Wake Forest University |
Flüssige Analoge zur Behandlung viraler Infektionen
|
US6911216B1
(en)
|
1994-10-12 |
2005-06-28 |
Genzyme Corporation |
Targeted delivery via biodegradable polymers
|
RU2166512C2
(ru)
*
|
1995-01-16 |
2001-05-10 |
Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн |
Конъюгаты терапевтического соединения с жирной кислотой
|
EP0754451A1
(de)
*
|
1995-01-27 |
1997-01-22 |
Palomino Munoz, Juan Manuel |
Liposom zur zerströrung von hiv und von mit diesem virus infizierten zellen
|
ES2088752B1
(es)
*
|
1995-01-27 |
1997-03-01 |
Palomino Munoz Juan Manuel |
Liposomas especificos para la eliminaci0n de vih y celulas infectadas por el mismo.
|
DZ1965A1
(fr)
*
|
1995-02-06 |
2002-07-17 |
Astra Ab |
Composition pharmaceutique nouvelle.
|
TW438585B
(en)
|
1995-02-06 |
2001-06-07 |
Astra Ab |
Pharmaceutical compositions for topical administration for prophylaxis and/or treatment of herpesvirus infections
|
DE19505168A1
(de)
*
|
1995-02-16 |
1996-08-22 |
Boehringer Mannheim Gmbh |
Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
|
CA2219119C
(en)
|
1995-05-04 |
2012-10-23 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
DE69636734T2
(de)
*
|
1995-06-07 |
2007-10-18 |
Emory University |
Nucleoside mit anti-hepatitis b virus wirksamkeit
|
US5756122A
(en)
*
|
1995-06-07 |
1998-05-26 |
Georgetown University |
Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
|
US7517858B1
(en)
*
|
1995-06-07 |
2009-04-14 |
The Regents Of The University Of California |
Prodrugs of pharmaceuticals with improved bioavailability
|
US6313106B1
(en)
|
1995-06-07 |
2001-11-06 |
D-Pharm Ltd. |
Phospholipid derivatives of valproic acid and mixtures thereof
|
US6844326B2
(en)
*
|
1995-06-07 |
2005-01-18 |
Anticancer, Inc. |
Treatment of alopecia
|
DE19602757A1
(de)
*
|
1996-01-26 |
1997-07-31 |
Boehringer Mannheim Gmbh |
Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
|
US6025155A
(en)
*
|
1996-04-10 |
2000-02-15 |
Chromos Molecular Systems, Inc. |
Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
|
US20030033617A1
(en)
*
|
1996-04-10 |
2003-02-13 |
Gyula Hadlaczky |
Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
|
US20020160970A1
(en)
*
|
1996-04-10 |
2002-10-31 |
Gyula Hadlaczky |
Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
|
US6077697A
(en)
*
|
1996-04-10 |
2000-06-20 |
Chromos Molecular Systems, Inc. |
Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
|
JP4172726B2
(ja)
*
|
1996-05-22 |
2008-10-29 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
|
US5919815A
(en)
*
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
US6576636B2
(en)
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
IL118626A0
(en)
*
|
1996-06-11 |
1996-10-16 |
Xtl Biopharmaceuticals Limited |
Anti HBV antibody
|
EP1611885A1
(de)
*
|
1996-07-26 |
2006-01-04 |
Susan P. Perrine |
Verwendung eines induzierenden Wirkstoffes zur Behandlung von Blut, Viralen und zellulären Störungen
|
US6686462B2
(en)
*
|
1997-02-28 |
2004-02-03 |
The Regents Of The University Of California |
Antiviral compounds and methods of administration
|
CA2287370C
(en)
|
1997-03-19 |
2010-02-09 |
Emory University |
Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
|
US20090239940A1
(en)
*
|
1997-07-22 |
2009-09-24 |
Del Monte Federica |
Treating heart failure and ventricular arrhythmias
|
WO1999006563A1
(en)
|
1997-07-30 |
1999-02-11 |
Emory University |
Novel bone mineralization proteins, dna, vectors, expression systems
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
US6197764B1
(en)
|
1997-11-26 |
2001-03-06 |
Protarga, Inc. |
Clozapine compositions and uses thereof
|
US6153653A
(en)
*
|
1997-11-26 |
2000-11-28 |
Protarga, Inc. |
Choline compositions and uses thereof
|
US5955459A
(en)
*
|
1997-11-26 |
1999-09-21 |
Neuromedica, Inc. |
Fatty acid-antipsychotic compositions and uses thereof
|
US5977174A
(en)
*
|
1997-11-26 |
1999-11-02 |
Neuromedica, Inc. |
Cholinergic compositions and uses thereof
|
AU774861B2
(en)
|
1998-02-11 |
2004-07-08 |
Douglas V Faller |
Compositions and methods for the treatment of cystic fibrosis
|
DE69933860T2
(de)
|
1998-02-25 |
2007-05-31 |
Emory University |
2'-fluoronukleoside
|
US6194379B1
(en)
|
1998-05-01 |
2001-02-27 |
Abbott Laboratories |
Elemental enteral formula
|
MXPA01001507A
(es)
*
|
1998-08-10 |
2003-09-10 |
Novirio Pharmaceuticals Ltd |
°l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
|
US6444652B1
(en)
|
1998-08-10 |
2002-09-03 |
Novirio Pharmaceuticals Limited |
β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
|
EP1431304B1
(de)
|
1998-08-10 |
2014-12-03 |
Novartis AG |
Beta-L-2'-Deoxy-Nukleoside für die Behandlung von Hepatitis B
|
US6020483A
(en)
*
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
EP1382343B1
(de)
|
1998-11-02 |
2010-02-17 |
Gilead Sciences, Inc. |
Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
|
IL127143A0
(en)
|
1998-11-19 |
1999-09-22 |
Dpharm Ltd |
Phospholipid terivatives of non-steroidal anti inflammatory drugs
|
US6818227B1
(en)
|
1999-02-08 |
2004-11-16 |
Alza Corporation |
Liposome composition and method for administration of a radiosensitizer
|
US7235583B1
(en)
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
IL131887A0
(en)
|
1999-09-14 |
2001-03-19 |
Dpharm Ltd |
Phospholipid prodrugs of anti-proliferative drugs
|
US7026469B2
(en)
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
US6716825B2
(en)
|
1999-12-03 |
2004-04-06 |
The Regents Of The University Of California |
Phosphonate compounds
|
PT1284720E
(pt)
*
|
2000-03-29 |
2006-12-29 |
Cornell Res Foundation Inc |
L-fmau para o tratamento de infecção viral por hepatite delta
|
US6761901B1
(en)
|
2000-05-02 |
2004-07-13 |
Enzrel Inc. |
Liposome drug delivery
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
KR20080021797A
(ko)
|
2000-05-26 |
2008-03-07 |
이데닉스(케이만)리미티드 |
플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
|
US6875751B2
(en)
*
|
2000-06-15 |
2005-04-05 |
Idenix Pharmaceuticals, Inc. |
3′-prodrugs of 2′-deoxy-β-L-nucleosides
|
US6689760B1
(en)
|
2000-07-10 |
2004-02-10 |
Enzrel Inc. |
Anti-mycobacterial compositions
|
US6455073B1
(en)
|
2000-07-10 |
2002-09-24 |
Enzrel, Inc. |
Covalent microparticle-drug conjugates for biological targeting
|
US7015200B2
(en)
|
2000-09-22 |
2006-03-21 |
Orphan Medical, Inc. |
Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
|
EP2166087B1
(de)
*
|
2000-09-28 |
2012-11-14 |
Bioriginal Food & Science Corp. |
FAD6, Mitglied der Desaturase-Familie und Verwendungen davon
|
US20050059031A1
(en)
|
2000-10-06 |
2005-03-17 |
Quantum Dot Corporation |
Method for enhancing transport of semiconductor nanocrystals across biological membranes
|
KR20040028657A
(ko)
|
2000-10-18 |
2004-04-03 |
파마셋, 리미티드 |
바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드
|
US7309696B2
(en)
|
2000-10-19 |
2007-12-18 |
Wake Forest University |
Compositions and methods for targeting cancer cells
|
KR101150250B1
(ko)
*
|
2001-03-01 |
2012-06-12 |
아보트 래버러토리즈 |
시스-ftc의 다형 및 기타 결정형
|
US8552054B2
(en)
*
|
2001-03-23 |
2013-10-08 |
Luitpold Pharmaceuticals, Inc. |
Fatty amine drug conjugates
|
JP4634694B2
(ja)
*
|
2001-03-23 |
2011-02-16 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪アルコール薬物複合体
|
US20030212051A1
(en)
*
|
2001-04-06 |
2003-11-13 |
Polli James E |
Bile acid containing prodrugs with enhanced bioavailabilty
|
WO2003021959A1
(en)
|
2001-08-31 |
2003-03-13 |
Thomson Licensing Sa |
Sequence counter for an audio visual stream
|
AU2002330154A1
(en)
*
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
US7045543B2
(en)
|
2001-11-05 |
2006-05-16 |
Enzrel Inc. |
Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
|
SE521676C2
(sv)
*
|
2002-01-02 |
2003-11-25 |
Dilafor Ab |
Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
|
JP2005523249A
(ja)
*
|
2002-01-09 |
2005-08-04 |
エンズレル インコーポレイテッド |
多環式芳香族抗酸化剤または抗炎症化合物のリポソーム薬物配達
|
JP2005526497A
(ja)
*
|
2002-02-04 |
2005-09-08 |
ビオミラ,インコーポレーテッド |
免疫刺激性、共有結合性脂質化オリゴヌクレオチド
|
EA200401565A1
(ru)
*
|
2002-05-24 |
2005-04-28 |
Неофарм, Инк. |
Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
|
WO2003099830A2
(en)
*
|
2002-05-24 |
2003-12-04 |
Neopharm, Inc. |
Cardiolipin compositions, methods of preparation and use
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
CA2489552A1
(en)
*
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
CN101172993A
(zh)
*
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
DE14169110T1
(de)
|
2002-06-28 |
2022-05-12 |
Centre National De La Recherche Scientifique -Cnrs- |
Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
|
TWI244393B
(en)
*
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
US7186700B2
(en)
*
|
2002-09-13 |
2007-03-06 |
Idenix Pharmaceuticals, Inc. |
β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
|
US20050277611A1
(en)
*
|
2002-10-16 |
2005-12-15 |
Neopharm, Inc. |
Cationic cardiolipin analoges and its use thereof
|
MXPA05005192A
(es)
*
|
2002-11-15 |
2005-09-08 |
Idenix Cayman Ltd |
Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
|
WO2004052899A2
(en)
*
|
2002-12-12 |
2004-06-24 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
KR20050110611A
(ko)
*
|
2002-12-23 |
2005-11-23 |
이데닉스 (케이만) 리미티드 |
3'-뉴클레오사이드 프로드럭의 생산 방법
|
EP1460082A1
(de)
*
|
2003-03-19 |
2004-09-22 |
Heidelberg Pharma Holding GmbH |
Phospholipidester von clofarabin-derivate
|
JP5107573B2
(ja)
*
|
2003-04-25 |
2012-12-26 |
ザ ペン ステイト リサーチ ファウンデーション |
増殖抑制性脂質由来生物活性化合物の全身送達方法およびシステム
|
SI3521297T1
(sl)
|
2003-05-30 |
2022-04-29 |
Gilead Pharmasset Llc |
Modificirani fluorirani nukleozidni analogi
|
US20060078560A1
(en)
*
|
2003-06-23 |
2006-04-13 |
Neopharm, Inc. |
Method of inducing apoptosis and inhibiting cardiolipin synthesis
|
DE602004028841D1
(de)
|
2003-07-25 |
2010-10-07 |
Centre Nat Rech Scient |
Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
|
WO2005023292A1
(en)
|
2003-09-03 |
2005-03-17 |
The General Hospital Corporation |
Methods of treating restenosis
|
PL2574341T3
(pl)
|
2004-03-29 |
2017-09-29 |
University Of South Florida |
Efektywne leczenie guzów i raka fosforanem tricyrybiny
|
WO2006000922A2
(en)
*
|
2004-06-23 |
2006-01-05 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
ES2725457T3
(es)
*
|
2004-09-14 |
2019-09-24 |
Gilead Pharmasset Llc |
Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
|
EP1812012A4
(de)
|
2004-11-15 |
2010-02-17 |
Ceptyr Inc |
Protein-tyrosin-phosphatasehemmer und verfahren zu ihrer verwendung
|
WO2006110655A2
(en)
|
2005-04-08 |
2006-10-19 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
WO2006110656A2
(en)
*
|
2005-04-08 |
2006-10-19 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of viral infections and other medical disorders
|
NZ609146A
(en)
*
|
2005-09-26 |
2014-08-29 |
Gilead Pharmasset Llc |
Modified 4’-nucleosides as antiviral agents
|
NO324263B1
(no)
*
|
2005-12-08 |
2007-09-17 |
Clavis Pharma Asa |
Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
|
WO2007075876A2
(en)
*
|
2005-12-23 |
2007-07-05 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
EP1994043A4
(de)
|
2006-02-10 |
2009-05-20 |
Univ Cincinnati |
Phosphatasehemmer-protein 1 als regulator der herzfunktion
|
US8895531B2
(en)
*
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
GB0608876D0
(en)
|
2006-05-05 |
2006-06-14 |
Medivir Ab |
Combination therapy
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2009009625A2
(en)
|
2007-07-09 |
2009-01-15 |
Eastern Virginia Medical School |
Substituted nucleoside derivatives with antiviral and antimicrobial properties
|
BRPI0817234A2
(pt)
*
|
2007-09-26 |
2014-09-30 |
Sinai School Medicine |
Análogos de azacitidina e seus usos
|
EP2070938A1
(de)
|
2007-12-13 |
2009-06-17 |
Heidelberg Pharma AG |
Clofarabin-Dietherphospholipid-Derivate
|
JP5562255B2
(ja)
*
|
2008-01-25 |
2014-07-30 |
キメリクス,インコーポレイテッド |
ウイルス感染を治療する方法
|
EP2262808B1
(de)
|
2008-03-28 |
2013-08-14 |
Altiris Therapeutics |
Chemokinrezeptormodulatoren
|
WO2009129120A2
(en)
|
2008-04-15 |
2009-10-22 |
Rfs Pharma, Llc |
Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
NZ593649A
(en)
*
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
CA2748057C
(en)
*
|
2008-12-23 |
2018-07-03 |
Pharmasset, Inc. |
Nucleoside phosphoramidates
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
TWI583692B
(zh)
*
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2011011519A1
(en)
|
2009-07-21 |
2011-01-27 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
WO2011038224A1
(en)
|
2009-09-24 |
2011-03-31 |
Trustees Of Boston University |
Methods for treating viral disorders
|
AU2010326132B9
(en)
|
2009-12-01 |
2014-10-02 |
Translate Bio, Inc. |
Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
|
US8618068B2
(en)
|
2009-12-08 |
2013-12-31 |
Trustees Of Boston University |
Methods and low dose regimens for treating red blood cell disorders
|
HUE032860T2
(en)
|
2010-02-12 |
2017-11-28 |
Chimerix Inc |
A method for treating a virus infection
|
WO2011113013A2
(en)
|
2010-03-11 |
2011-09-15 |
Hemaquest Pharmaceuticals, Inc. |
Methods and compositions for treating viral or virally-induced conditions
|
KR101715981B1
(ko)
|
2010-03-31 |
2017-03-13 |
길리애드 파마셋 엘엘씨 |
뉴클레오사이드 포스포르아미데이트
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
AU2011248620B2
(en)
|
2010-04-26 |
2015-11-26 |
Chimerix, Inc. |
Methods of treating retroviral infections and related dosage regimes
|
US8884027B2
(en)
|
2010-10-22 |
2014-11-11 |
University Of Rochester |
Melampomagnolide B derivatives as antileukemic and cytotoxic agents
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
EP3042910B1
(de)
|
2010-11-30 |
2019-01-09 |
Gilead Pharmasset LLC |
2'-spiro-nukleoside zur therapie von hepatitis c
|
CN111671918A
(zh)
|
2011-06-08 |
2020-09-18 |
川斯勒佰尔公司 |
Mrna递送的脂质纳米颗粒组合物和方法
|
DK3336082T3
(da)
|
2011-06-08 |
2020-04-27 |
Translate Bio Inc |
Spaltelige lipider
|
DE202012013382U1
(de)
|
2011-09-16 |
2016-08-23 |
Gilead Pharmasset Llc |
Zusammensetzungen zur Behandlung von HCV
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
CA3131037A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
US9546128B2
(en)
|
2012-03-29 |
2017-01-17 |
Shire Human Genetic Therapies, Inc. |
Ionizable cationic lipids
|
JP6211054B2
(ja)
|
2012-03-29 |
2017-10-11 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
脂質誘導される中性ナノ粒子
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
BR112015009002B1
(pt)
*
|
2012-10-25 |
2020-02-27 |
Société des Produits Nestlé S.A. |
Peptídeos amargos encapsulados, seu método de encapsulamento, e composições nutritivas
|
PT2950786T
(pt)
|
2013-01-31 |
2020-03-03 |
Gilead Pharmasset Llc |
Formulação de combinação de dois compostos antivirais
|
TR201901310T4
(tr)
|
2013-03-14 |
2019-02-21 |
Translate Bio Inc |
Mesajcı RNA'nın saflaştırılması yöntemleri.
|
IL305374A
(en)
|
2013-03-14 |
2023-10-01 |
Ethris Gmbh |
CFTR mRNA Assemblies and Related Methods and Uses
|
ES2670529T3
(es)
|
2013-03-15 |
2018-05-30 |
Translate Bio, Inc. |
Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas
|
SI3650014T1
(sl)
|
2013-08-27 |
2022-01-31 |
Gilead Pharmasset Llc |
Formulacija kombinacije dveh protivirusnih spojin
|
US11224642B2
(en)
|
2013-10-22 |
2022-01-18 |
Translate Bio, Inc. |
MRNA therapy for argininosuccinate synthetase deficiency
|
WO2015061491A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for phenylketonuria
|
WO2015137983A1
(en)
|
2014-03-14 |
2015-09-17 |
Alltech, Inc. |
Compositions of selenoorganic compounds and methods of use thereof
|
CN106164248B
(zh)
|
2014-04-25 |
2019-10-15 |
川斯勒佰尔公司 |
信使rna的纯化方法
|
WO2017048252A1
(en)
|
2015-09-15 |
2017-03-23 |
Alltech, Inc. |
Compositions of selenoorganic compounds and methods of use thereof
|
US11253605B2
(en)
|
2017-02-27 |
2022-02-22 |
Translate Bio, Inc. |
Codon-optimized CFTR MRNA
|
WO2018213476A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
EP3638215A4
(de)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
Rna-formulierungen
|
CA3073211A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
CN114206447A
(zh)
|
2019-05-31 |
2022-03-18 |
维拉克塔附属公司 |
用组蛋白脱乙酰基酶抑制剂治疗病毒相关的癌症的方法
|
WO2022031761A2
(en)
*
|
2020-08-03 |
2022-02-10 |
Sepelo Therapeutics, Llc |
Targeted delivery of therapeutic agents
|
BR112023002951A2
(pt)
|
2020-08-24 |
2023-03-21 |
Gilead Sciences Inc |
Compostos de fosfolipídio e usos destes
|
EP4108251A1
(de)
|
2021-06-22 |
2022-12-28 |
Solmic Biotech GmbH |
Griffithsin zur verwendung in einem verfahren zur vorbeugung oder behandlung von infektionen mit respiratorischen viren
|
EP4306130A1
(de)
|
2022-07-11 |
2024-01-17 |
Solmic Biotech GmbH |
Inhalierbare formulierung zur verwendung bei der behandlung von bakteriellen lungeninfektionen
|